

Amendments to the Claims:

This listing of the claims will replace all prior versions and listing of claims in the application.

Please cancel claims 75, 109, 110, 117 to 128, 135 to 142, 149 to 155 without prejudice or disclaimer.

Please amend claims 156 to 159 as follows:

1 to 155. (cancelled)

156. (currently amended) A method of delivering a drug to a subject comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a nucleic acid encoding a chimeric protein comprising (i) a first protein comprising the amino acid sequence of SEQ ID NO: 51, said amino acid sequence being capable of specifically binding to the gastro-intestinal receptor HPT1 (SEQ ID NO: 178), which comprises said first protein being fused via a covalent bond to a second protein, wherein the second protein acts as a drug; and (ii) a pharmaceutically acceptable carrier,

157. (currently amended) A method of delivering an active agent in vivo comprising administering to a subject a composition comprising an isolated protein comprising the amino acid sequence of SEQ ID NO: 51, said amino acid sequence being capable of specifically binding to the gastro-intestinal receptor HPT1 (SEQ ID NO: 178), wherein the isolated protein is bound to a material comprising an active agent selected from the group consisting of an antigen, imaging agent and drug.

158. (currently amended) A method of delivering a drug to a subject comprising administering to the subject a composition comprising an isolated protein comprising the amino acid sequence of SEQ ID NO: 51, said amino acid sequence being capable of specifically binding to the gastro-intestinal receptor HPT1 (SEQ ID NO: 178), wherein the isolated protein is covalently bound to a particle containing the drug.

159. (currently amended) A method of delivering a drug to a subject comprising administering to the subject a composition comprising an isolated protein comprising the amino acid sequence of SEQ ID NO: 51, said amino acid sequence being capable of specifically binding to the gastro-intestinal receptor

HPT1 (SEQ ID NO: 178), wherein the isolated protein is covalently bound to the drug.

160. (previously presented) The method of claim 157 wherein the active agent is a drug.

161. (previously presented) The method of claim 157 wherein the material is a particle containing the active agent.

162. (previously presented) The method as in any one of claims 157 to 159 wherein the isolated protein consists essentially of the amino acid sequence of SEQ ID NO: 51.

163. (previously presented) The method as in any one of claims 157 to 159 wherein the isolated protein facilitates the transport of the active agent through human or animal gastro-intestinal tissue.

164. (previously presented) The method as in any one of claims 156 to 159 wherein the administration is oral.

165. (previously presented) The method as in any one of claims 156 to 159 wherein the subject is human.